Buy Laennec solution 2 ml 50 pcs
  • Buy Laennec solution 2 ml 50 pcs

Laennec®

Clinic Rana
1905 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$2,753.94
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Laennec - immunomodulatory and hepatoprotective drug.

The drug exhibits immunomodulating properties due to its ability to stimulate humoral immunity and increase the functional activity of phagocytes and natural killer cells. Increases the bactericidal activity of peripheral blood leukocytes, manifested in their ability to destroy the captured pathogen. The cytokines that make up the drug activate the metabolic and supervisory functions of skin cells.

Biologically active substances contained in the hydrolyzate stimulate the regeneration (proliferation) of hepatocytes, exhibit detoxification properties, reduce the deposition of lipids and cholesterol in liver cells, increase the activity of tissue respiration, activate metabolism in the liver, reduce the development of connective tissue in the liver.

Indications

  • chronic recurrent herpes (as part of complex therapy);
  • moderate and severe atopic dermatitis, incl. complicated (as part of complex therapy);
  • chronic liver diseases: steatohepatitis (alcoholic, metabolic and mixed etiology) - in the form of monotherapy.

Composition

1 ampoule contains:
Active ingredient: hydrolyzed human placenta 112 mg
Excipients: water for injection, sodium hydroxide or hydrochloric acid (for pH adjustment).

No customer reviews for the moment.

Write your review

Write your review

Laennec®

Dosage and Administration

In chronic recurrent herpes and atopic dermatitis, the drug is administered intravenously: 10 ml (560 mg of placental hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose or saline and injected through the ulnar vein for 1.5-2 h. Injections are carried out 3 times a week with an interval of 2 days. The course of treatment 10 injections.

In chronic liver diseases (steatohepatitis / alcoholic, metabolic, and mixed etiology /), the drug is administered intramuscularly at 2 ml / day (112 mg of placental hydrolyzate). Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (6 ml) / day. The drug can be administered intravenously in a drip: 10 ml (560 mg of placenta hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the ulnar vein for 1.5-2 hours. Injections are performed 2 times in Week. The course of treatment is 2-3 weeks.

Adverse reactions

Side effects are observed in 3.7% of patients.

Clinically significant adverse reactions: allergic reactions are possible.

Other adverse effects: soreness at the injection site (2.56%), allergic reactions (redness, pruritus) (0.37%), numbness at the injection site (0.37%), gynecomastia (0.37%) - the cause-and-effect relationship with the administration of the drug has not been established .

Contraindications

WITHcaution should be used in patients with polyvalent allergies to drugs, in the elderly.

Drug interactions

When mixing the Laennec solution with other drugs, which are strong bases (pH above 8.5), the activity of the drug decreases.

To date, no other clinically significant drug drug interactions have been identified.

Pregnancy and Lactation

The drug is contraindicated during pregnancy and during breastfeeding.

Special instructions

According to the data currently available, the drug can be prescribed to elderly people. However, given that the physiological functions in elderly people are deteriorating, the drug should be used under close supervision.

Use in Pediatrics

Studies on the safety of Laennec in newborns (including premature infants) and minor children have not been conducted. Use in children is not recommended.

Overdosage

Currently, cases of drug overdose Laennec were reported.

  • Brand name: Laennec
  • Active ingredient: Human placenta hydrolyzate
  • Dosage form: Injection
  • Manufacturer: Clinic Rana
  • Country of Origin: Japan

Studies and clinical trials of Laennec (Click to expand)

  1. A rheumatic syndrome with Laennec's cirrhosis
  2. Comparing quality of life following liver transplantation for Laennec's versus non-Laennec's patients
  3. Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy
  4. The discovery of the stethoscope by T. R. H. Laënnec (1781–1826)
  5. Towards evidence-based percutaneous coronary intervention: The Rene Laennec lecture in clinical cardiology
  6. Unilateral pleural effusion without clinical ascites in Laennec's cirrhosis
  7. Zum 100. Todestag von René-Théophile Laennec
  8. Homologus serum hepatitis occurring in Laennec's cirrhosis
  9. Plasma and urinary amino acids in laennec's cirrhosis
  10. The pattern of serum triglyceride fatty acids in Laennec's cirrhosis
  11. Fatal diffuse haemorrhage in cases of laennec’s liver cirrhosis
  12. Researches on Laennec’s vesicular emphysema, with observations on paralysis of the intercostal muscles and diaphragm, considered as a new source of diagnosis
  13. Laennec: A great student of tuberculosis
  14. Laennec
  15. René Laennec (1781–1826) and the Invention of the Stethoscope
  16. Plague. Laennec (1782– 1826) Inventor of the Stethoscope and Father of Modern Medicine: by Arthur N. Foxe, M.D., Hobson Book Press. 52, Vanderbilt Avenue, New York. Pp. 122, 2 ill. price $2.50
  17. Auscultation before Laennec
  18. The life and work of C.J.B. Williams (1805–1889) an eminent pupil of Laennec
  19. Ancienne Externe des Hôpitaux de Paris ,Histoire des idées sur la guérison des cavernes depuis laënnec Pp. 74 (1937) Amédée Legrand,Paris.
  20. The life and discoveries of René Laennec
  21. THE PATHOLOGY OF SUBCHRONIC ATROPHY OF THE LIVER : A Comparison with Cirrhosis hepatis Laennec.
  22. Redefining the natural history of calcific aortic stenosis: lessons from Laennec
  23. ABOUT THE COVER LAENNEC AND THE STETHESCOPE
  24. HOST FACTORS CAUSING INCREASED SUSCEPTIBILITY TO INFECTION IN PATIENTS WITH LAENNEC'S CIRRHOSIS

8 other products in the same category:

arrow_upward